Market Research Logo

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) Overview
Therapeutics Development
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Stage of Development
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Therapy Area
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Indication
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Companies
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Products under Development by Universities/Institutes
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Array BioPharma Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Creabilis SA
Daiichi Sankyo Company, Limited
Dompe Farmaceutici S.p.A.
Genzyme Corporation
Glenmark Pharmaceuticals Ltd.
Ignyta, Inc.
Loxo Oncology, Inc.
Mimetogen Pharmaceuticals Inc.
Nerviano Medical Sciences S.r.l.
Purdue Pharma L.P.
SOM Innovation Biotech SL
Tiziana Life Sciences Plc
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles
AR-523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-786 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7962 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-64 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-7451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRB-0089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBR-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-389988 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lestaurtinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LOXO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-626 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tavilermide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-902A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Projects
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Featured News & Press Releases
Jul 13, 2016: Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101
Jun 15, 2016: Loxo Oncology Accepts Invitation to Present LOXO-101 to the FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee
Apr 19, 2016: Loxo Oncology Announces First Pediatric Response to LOXO-101
Apr 17, 2016: Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update
Apr 17, 2016: Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting
Apr 11, 2016: Loxo Oncology to Present Updated LOXO-101 Phase 1 Data at the 2016 AACR Annual Meeting
Apr 07, 2016: Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting
Jan 15, 2016: Loxo Oncology Announces EMA Orphan Drug Designation Granted to LOXO-101 for Treatment of Soft Tissue Sarcoma
Dec 22, 2015: Loxo Oncology Announces First Patient Enrolled in Phase 1 Trial of LOXO-101 in Pediatric Cancer Patients
Dec 09, 2015: Ignyta Announces Initiation of STARTRK Next Generation Phase 1/1b Pediatric Clinical Trial of Entrectinib
Dec 08, 2015: Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma
Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
Nov 30, 2015: Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program
Nov 08, 2015: Loxo Oncology TRK Inhibitor LOXO-101 Demonstrates Promising Clinical Activity and Safety in Phase 1 Trial
Oct 28, 2015: Loxo Oncology Announces Selection of LOXO-101 for NCI-MATCH Precision Medicine Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Array BioPharma Inc., H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by Creabilis SA, H2 2016
Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Pipeline by Genzyme Corporation, H2 2016
Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
Pipeline by Ignyta, Inc., H2 2016
Pipeline by Loxo Oncology, Inc., H2 2016
Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016
Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
Pipeline by Purdue Pharma L.P., H2 2016
Pipeline by SOM Innovation Biotech SL, H2 2016
Pipeline by Tiziana Life Sciences Plc, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Dormant Projects (Contd..3), H2 2016
Dormant Projects (Contd..4), H2 2016
Discontinued Products, H2 2016
Discontinued Products (Contd..1), H2 2016
Discontinued Products (Contd..2), H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report